Clinical trials: Unspecified Adult Solid Tumor, Protocol Specific, completed
Unspecified Adult Solid Tumor, Protocol Specific
Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00112892
- Testing
- selenium, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Roswell Park Cancer Institute
Unspecified Adult Solid Tumor, Protocol Specific
Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining paclitaxel with ABI-007 may kill more tumor cells.
- Trial name
- NCT00095914
- Testing
- paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors
RATIONALE: Understanding how oxaliplatin affects hearing loss, dizziness, and peripheral neuropathy may improve the ability to plan effective treatment for patients receiving oxaliplatin for solid tumors.
- Trial name
- NCT00305799
- Testing
- management of therapy complications
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- Case Comprehensive Cancer Center
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy
RATIONALE: Patient education may improve the effectiveness of ondansetron in preventing nausea and vomiting in patients receiving chemotherapy.
- Trial name
- NCT00005994
- Testing
- ondansetron
- Where
- 4 sites in United States
- Sponsor
- University of Rochester
Unspecified Adult Solid Tumor, Protocol Specific
TNF-Bound Colloidal Gold in Treating Patients With Advanced Solid Tumors
RATIONALE: Biological therapies, such as TNF-bound colloidal gold, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00356980
- Testing
- colloidal gold-bound tumor necrosis factor, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Pain, Unspecified Adult Solid Tumor, Protocol Specific
Valdecoxib in Treating Chronic Pain in Cancer Patients
RATIONALE: Valdecoxib may be effective in relieving chronic pain in cancer patients. It is not yet known if valdecoxib is effective in treating chronic pain.
- Trial name
- NCT00021996
- Testing
- valdecoxib
- Where
- 2 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Unspecified Adult Solid Tumor, Protocol Specific
Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy such as docetaxel work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00084786
- Testing
- docetaxel, gefitinib
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function
This is an open-label non-randomized study in subjects with advanced or metastatic solid tumors who are no longer responding to available therapy. HALAVEN will be administered to subjects on Days 1 and 8 of a 21-day cycle.
- Trial name
- NCT01418677
- Testing
- E7389
- Where
- 9 sites in United States
- Volunteers
- 19 people
- Sponsor
- Eisai Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Vaccine Therapy in Treating Patients With Advanced Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced cancer.
- Trial name
- NCT00004881
- Testing
- MVA-MUC1-IL2 vaccine
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the bad side effects of…
- Trial name
- NCT00003144
- Testing
- amifostine trihydrate, cisplatin, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- NYU Langone Health
Unspecified Adult Solid Tumor, Protocol Specific
Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of vorinostat and gemcitabine in treating patients with metastatic or unresectable solid tumors.
- Trial name
- NCT00243100
- Testing
- vorinostat, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer
RATIONALE: Tissue plasminogen activator and captopril may help the body generate angiostatin. Angiostatin may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00086723
- Testing
- recombinant tissue plasminogen activator, captopril
- Where
- United States
- Sponsor
- Northwestern University
Unspecified Adult Solid Tumor, Protocol Specific
MS 209 Plus Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004886
- Testing
- docetaxel, dofequidar fumarate
- Where
- 3 sites in France, Germany
- Volunteers
- 30 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Chronic Myeloproliferative Disorders, Fatigue
St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer
RATIONALE: Giving St. John's wort may be effective in relieving fatigue in patients with cancer who are undergoing chemotherapy or hormone therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of St.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00005805
- Testing
- St. John's wort
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anorexia, Cachexia
Creatine in Treating Patients With Cancer-Associated Weight Loss
RATIONALE: It is not yet known whether the supplement creatine is effective in increasing weight and improving appetite and quality of life in patients who have cancer.
- Conditions
- Anorexia, Cachexia, Unspecified Adult Solid Tumor, Protocol Specific, Weight Changes
- Trial name
- NCT00081250
- Testing
- creatine monohydrate
- Where
- 220 sites in United States
- Volunteers
- 300 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Unspecified Adult Solid Tumor, Protocol Specific
Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells…
- Trial name
- NCT00253344
- Testing
- docetaxel, lenalidomide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Case Comprehensive Cancer Center
Ovarian Sarcoma, Ovarian Stromal Cancer
Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of temsirolimus, carboplatin, and paclitaxel in treating patients with advanced solid tumors.
- Conditions
- Ovarian Sarcoma, Ovarian Stromal Cancer, Recurrent Endometrial Carcinoma, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT00408655
- Testing
- paclitaxel, carboplatin, temsirolimus
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor stem cell helps stop the growth of cancer or abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00003816
- Testing
- anti-thymocyte globulin, busulfan, carboplatin
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- Roswell Park Cancer Institute
Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
MEN-10755 in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of MEN-10755 in treating patients who have solid tumors.
- Trial name
- NCT00003982
- Testing
- sabarubicin
- Where
- 27 sites in Austria, Belgium and 7 more
- Volunteers
- 30 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma, Small Intestine Cancer
CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy
RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have solid tumors and/or lymphoma that did not respond to…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00031941
- Testing
- lenalidomide
- Where
- 2 sites in United States
- Sponsor
- National Institutes of Health Clinical Center (CC)